762286-24-8

Basic information

• Product Name: 1-Pyrrolidinecarboxamide, N-methyl-3-(methylamino)-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-, (3S)-
• CAS NO: 762286-24-8
• Molecular Formula: C18H28N4O
• Molecular Weight: 316.447
• Mol File: 762286-24-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxamide, N-methyl-3-(methylamino)-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-, (3S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxamide, N-methyl-3-(methylamino)-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-, (3S)-(762286-24-8)
• EPA Substance Registry System: 1-Pyrrolidinecarboxamide, N-methyl-3-(methylamino)-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-, (3S)-(762286-24-8)

Safety Data

• Hazardous Substances Data: 762286-24-8(Hazardous Substances Data)

Upstream product

• 762285-93-8 ((R)-1-benzylpyrrolidin-3-yl)-methyl-carbamic acid 4-nitrophenyl ester 
• 144043-17-4 (3R)-1-benzyl-N-methylpyrrolidin-3-amine 
• 862847-07-2 (R)-3-Hydroxy-pyrrolidine-1-carboxylic acid ((R)-1-benzyl-pyrrolidin-3-yl)-methyl-amide 
• 74-89-5 methylamine 
• 762285-62-1 {(S)-1-[((R)-1-Benzyl-pyrrolidin-3-yl)-methyl-carbamoyl]-pyrrolidin-3-yl}-methyl-carbamic acid tert-butyl ester 

Downstream Products

• 762285-62-1 {(S)-1-[((R)-1-Benzyl-pyrrolidin-3-yl)-methyl-carbamoyl]-pyrrolidin-3-yl}-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

Synthesis and structure-activity relationships of biarylcarboxamide bis-aminopyrrolidine urea derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1)

A novel series of bis-aminopyrrolidine ureas containing either a 4-biphenylcarboxmide or 5-phenyl-2-thiophenecarboxamide group have been identified as potent and functional antagonists of the melanin-concentrating hormone receptor-1. Syntheses and SAR are

MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, X, R1, R2, R3, R4, and R5 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.